For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

D.e. Shaw Research, LLC

USPTO Granted Patents = 31

EPO Patents = 9

Trademarks = 3

Forward Citations = 54

Loading Chart...

Loading Chart...

61 inventors (with patents filed for the assignee):

Fabrizio Giordanetto (10 out of 12 patents)

Alexander M Taylor (7 out of 28 patents)

Ron Dror (7 out of 7 patents)

4. Paul Maragakis (7 out of 7 patents)

5. Kevin J Bowers (6 out of 6 patents)

6. W Patrick Walters (5 out of 8 patents)

7. David E Shaw (5 out of 19 patents)

8. Thomas H McLean (4 out of 16 patents)

9. Mark Andrew Murcko (4 out of 56 patents)

10. J P Grossman (4 out of 4 patents)

11. André Lescarbeau (4 out of 11 patents)

12. Kelley C Shortsleeves (4 out of 7 patents)

13. Eric Therrien (4 out of 8 patents)

14. Jack Benjamin Greisman (4 out of 4 patents)

15. John K Salmon (3 out of 9 patents)

Core Competencies:

Machine Learning

PI3K Inhibitors

SHP2 Phosphatase

Neural Networks

Molecular Graph Generation

Particle Interactions

Voltage-Gated Proteins

Deep Learning

Computational Techniques

Dynamic Simulation

Hierarchical Tokenization

Zonal Methods

31 patents: Sort by Forward Citations

1. 12632623 - Modeling physical systems with large language machine-learned models (2026-05-19),

2. 12581252 - Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors (2026-03-17),

3. 12522605 - FGFR inhibitors and methods of use thereof (2026-01-13),

4. 12511482 - Multi-modal hierarchical tokenization deep neural network (2025-12-30),

5. 12331056 - SHP2 phosphatase inhibitors and methods of use thereof (2025-06-17),

6. 12219327 - Substituted isoindolines as PI3K-alpha inhibitors (2025-02-04),

7. 12217834 - Molecular graph generation from structural features using an artificial neural network (2025-02-04),

8. 12138263 - Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof (2024-11-12),

9. 11780845 - FGFR inhibitors and methods of use thereof (2023-10-10),

10. 11701354 - Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors (2023-07-18),

11. 11629145 - SHP2 phosphatase inhibitors and methods of use thereof (2023-04-18),

12. 11591336 - Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors (2023-02-28),

13. 11529347 - SHP2 phosphatase inhibitors and methods of use thereof (2022-12-20),

14. 11264120 - Suppressing interaction between bonded particles (2022-03-01),

15. 11139049 - Suppressing interaction between bonded particles (2021-10-05),

Company Overview

D.E. Shaw Research, LLC is a prominent research and development firm based in New York, specializing in advanced computational methods to accelerate drug discovery and molecular simulations. The organization leverages cutting-edge technology and innovative algorithms to model complex biological systems, aiming to enhance the understanding of molecular interactions and improve therapeutic outcomes. With a focus on biopharmaceutical applications, D.E. Shaw Research plays a significant role in the intersection of technology and life sciences.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

31 Patents

#280 in New York, NY

#654 in New York

#10,927 in US

#21,260 in the World

New York, NY, United States of America

D.e. Shaw Research, LLC

Forward Citations = 54

61 inventors:

Fabrizio Giordanetto (10 out of 12 patents)

Alexander M Taylor (7 out of 28 patents)

Ron Dror (7 out of 7 patents)

4. Paul Maragakis (7 out of 7 patents)

5. Kevin J Bowers (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: D.e. Shaw Research, LLC. Retrieved from https://idiyas.com/company/d-e-shaw-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…